News | April 07, 2022
Indian pharma growth likely to moderate in FY23: ICRA
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
The new reagents will bring the exceptional sensitivity of the company’s liquid format 1-step RT-qPCR reagents to a freeze-dryable format
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
BioFluidica LiquidScan harnesses the power of microfluidics
Iktos and Teijin Pharma will collaborate in developing new AI technology aiming to bring further improvement and speed to the drug design process
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
Ind-Ra maintains a neutral outlook for healthcare in FY23
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram
Subscribe To Our Newsletter & Stay Updated
